Literature DB >> 8228982

Interacting presynaptic kappa-opioid and GABAA receptors modulate dopamine release from rat striatal synaptosomes.

E Ronken1, A H Mulder, A N Schoffelmeer.   

Abstract

The presynaptic regulation of stimulated dopamine release from superfused rat striatal synaptosomes by opioids and gamma-aminobutyric acid (GABA) was studied. It was found that in addition to dopamine D2 autoreceptors, calcium-dependent K(+)-stimulated [3H]dopamine release was inhibited through activation of a homogeneous population of kappa-opioid receptors in view of the potent inhibitory effect of the kappa-selective agonist U69,593 (EC50 0.2 nM) and its antagonism by norbinaltorphimine. Neither mu- nor delta-selective receptor agonists affected release of [3H]-dopamine. In addition, GABA potently inhibited the evoked [3H]dopamine release (EC50 0.4 nM) through activation of GABAA receptors in view of the GABA-mimicking effect of muscimol, the sensitivity of its inhibitory effect to picrotoxin and bicuculline, and the absence of an effect of the GABAB receptor agonist baclofen. In the presence of a maximally effective concentration of GABA, U69,593 did not induce an additional release-inhibitory effect, indicating that these receptors and the presynaptic D2 receptor are colocalized on the striatal dopaminergic nerve terminals. The excitatory amino acid agonists N-methyl-D-aspartate and kainate, as well as the cholinergic agonist carbachol, stimulated [3H]dopamine release, which was subject to kappa-opioid receptor-mediated inhibition. In conclusion, striatal dopamine release is under regulatory control of multiple excitatory and inhibitory neurotransmitter by activation of colocalized presynaptic receptors for excitatory amino acids, acetylcholine, dopamine, dynorphins, and GABA within the dopaminergic nerve terminals. Together, these receptors locally control ongoing dopamine neurotransmission.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228982     DOI: 10.1111/j.1471-4159.1993.tb09797.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  21 in total

1.  Characterization of the decrease of extracellular striatal dopamine induced by intrastriatal morphine administration.

Authors:  T P Piepponen; J A Mikkola; M Ruotsalainen; D Jonker; L Ahtee
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

2.  Age-dependent effects of kappa-opioid receptor stimulation on cocaine-induced stereotyped behaviors and dopamine overflow in the caudate-putamen: an in vivo microdialysis study.

Authors:  A M Cortez; S Charntikov; T Der-Ghazarian; L R Horn; C A Crawford; S A McDougall
Journal:  Neuroscience       Date:  2010-05-05       Impact factor: 3.590

3.  Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes.

Authors:  Michael R Bruchas; Tara A Macey; Janet D Lowe; Charles Chavkin
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

4.  Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria.

Authors:  Tarsis F Brust; Jenny Morgenweck; Susy A Kim; Jamie H Rose; Jason L Locke; Cullen L Schmid; Lei Zhou; Edward L Stahl; Michael D Cameron; Sarah M Scarry; Jeffrey Aubé; Sara R Jones; Thomas J Martin; Laura M Bohn
Journal:  Sci Signal       Date:  2016-11-29       Impact factor: 8.192

Review 5.  Direct dopamine terminal regulation by local striatal microcircuitry.

Authors:  Suzanne O Nolan; Jennifer E Zachry; Amy R Johnson; Lillian J Brady; Cody A Siciliano; Erin S Calipari
Journal:  J Neurochem       Date:  2020-06-19       Impact factor: 5.372

Review 6.  Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse.

Authors:  Bronwyn M Kivell; Amy W M Ewald; Thomas E Prisinzano
Journal:  Adv Pharmacol       Date:  2014

7.  Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors.

Authors:  Hui Zhang; David Sulzer
Journal:  Basal Ganglia       Date:  2012-03-01

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Halothane anesthesia affects NMDA-stimulated cholinergic and GABAergic modulation of striatal dopamine efflux and metabolism in the rat in vivo.

Authors:  K J Whitehead; S Rose; P Jenner
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

10.  Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum.

Authors:  Brenda J Gehrke; Vladimir I Chefer; Toni S Shippenberg
Journal:  Psychopharmacology (Berl)       Date:  2008-02-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.